Health Catalyst, Inc. (HCAT) vs NRx Pharmaceuticals, Inc. (NRXP)

A side-by-side comparison of Health Catalyst, Inc. and NRx Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — HCAT vs NRXP

growth of $100 · dividends reinvested · last 7y
HCAT -95.5% (-35.8%/yr)NRXP -97.3% (-40.2%/yr)HCAT compounded faster over this window
0200400600Start $100202120232025$4$3
HCAT NRXP

HCAT vs NRXP: by the numbers

  • •HCAT is the larger company ($133M vs $126M market cap).
  • •Both run net losses; HCAT's is the smaller (-90.61% vs -691.81% net margin).

Metrics side by side

Valuation

MetricHCATNRXP
P/S ratio0.4636.99
P/B ratio1.32N/A
EV / EBITDA75.18N/A
FCF yield9.79%N/A

Profitability

MetricHCATNRXP
Gross margin33.47%58.78%
Operating margin-11.60%-1324.41%
Net margin-90.61%-691.81%
ROE-262.64%N/A
ROIC-21.42%N/A

Growth (annualized)

MetricHCATNRXP
Revenue CAGR (5Y)6.24%N/A
Total return CAGR (5Y)-48.35%-49.61%

Frequently asked

How have HCAT and NRXP total returns compared?
Over the past 5 years, HCAT delivered -48.35% and NRXP delivered -49.61% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.